Brief: Almirall Says Lebrikizumab Shows Control in Atopic Dermatitis For Up To Four Years
27/03/2026 13:56
March 27 (Reuters) - Almirall SA ALM.MC: LEBRIKIZUMAB DELIVERED LONG-TERM DISEASE CONTROL FOR UP TO FOUR YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS 94% OF PATIENTS ACHIEVED MEANINGFUL SKIN IMPROVEMENT (EASI-75) WITH UP TO FOUR YEARS OF LEBRIKIZUMAB TREATMENT 75% OF PATIENTS ACHIEVED NEAR-COMPLETE SKIN CLEARANCE, 78% EXPERIENCED MEANINGFUL ITCH RELIEF RESULTS FROM ONGOING PHASE 3B ADLONG STUDY Source text Further company coverage: ALM.MC (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24